Evaluation of exploratory fluid biomarkers from a phase 1 senolytic trial in mild Alzheimer’s disease

Evaluation of exploratory fluid biomarkers from a phase 1 senolytic trial in mild Alzheimer’s disease

Senescent cell accumulation contributes to the progression of age-related disorders including Alzheimer’s disease (AD). Clinical trials focused on cellular senescence are in early stages and have yet to establish reliable outcome measures reflecting senescent cell burden or response to senolytics, t...

Full description

Saved in:
Bibliographic Details
Main Authors: Valentina R. Garbarino, Juan Pablo Palavicini, Justin Melendez, Nicolas R. Barthelemy, Yingxin He, Tiffany F. Kautz, Marisa Lopez-Cruzan, Julia J. Mathews, Peng Xu, Bin Zhang, Afaf Saliba, Nagarjunachary Ragi, Kumar Sharma, Dallin Mason, Samuel Johnson, Suzanne Hendrix, Suzanne Craft, Ronald C. Petersen, Jair Machado Espindola-Netto, Ailing Xue, Tamara Tchkonia, James L. Kirkland, Arash Salardini, Nicolas Musi, Randall J. Bateman, Mitzi M. Gonzales, Miranda E. Orr
Format: Article
Language:English
Published: Elsevier 2025-07-01
Series:Neurotherapeutics
Subjects:
Alzheimer’s disease
Senolytics
Clinical trial
Biofluids
Biomarkers
Online Access:http://www.sciencedirect.com/science/article/pii/S1878747925000698
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S1878747925000698

Similar Items